The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Orally Disintegrating Drug Market Research Report 2025

Global Orally Disintegrating Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1739068

No of Pages : 92

Ask Your Query

Synopsis
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Global Orally Disintegrating Drug market is projected to reach US$ 3709.6 million in 2029, increasing from US$ 1957 million in 2022, with the CAGR of 9.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orally Disintegrating Drug market research.

The orally disintegrating drug market is being driven by several factors. One of the primary drivers is the growing demand for convenient and patient-friendly medication delivery methods. Orally disintegrating drugs offer an advantage over traditional oral tablets as they quickly dissolve in the mouth without the need for water, making them easier to administer, particularly for individuals with swallowing difficulties, pediatric patients, and the elderly. Additionally, the increasing prevalence of chronic diseases and the need for efficient and immediate drug absorption have fueled the demand for orally disintegrating drugs. Furthermore, advancements in formulation technologies and taste-masking techniques have improved the palatability of these drugs, enhancing patient compliance. Overall, the demand for orally disintegrating drugs is driven by the need for convenience, improved patient experience, and enhanced drug delivery options in the pharmaceutical market.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Orally Disintegrating Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Johnson and Johnson
  • GSK
  • Otsuka
  • Vartris
  • Teva
  • Pfizer
  • Eli Lilly and Company
  • Merck
  • Eisai
  • AstraZeneca
  • Bristol-Myers Squibb
  • Conquer

Segment by Type

  • Anti-Psychotics Drug
  • Anti-Epileptics Drug
  • Other

Segment by Application

  • CNS Diseases
  • Gastrointestinal Diseases
  • CVS Diseases
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Orally Disintegrating Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orally Disintegrating Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anti-Psychotics Drug
1.2.3 Anti-Epileptics Drug
1.2.4 Other
1.3 Market by Application
1.3.1 Global Orally Disintegrating Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 CNS Diseases
1.3.3 Gastrointestinal Diseases
1.3.4 CVS Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orally Disintegrating Drug Market Perspective (2018-2029)
2.2 Orally Disintegrating Drug Growth Trends by Region
2.2.1 Global Orally Disintegrating Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Orally Disintegrating Drug Historic Market Size by Region (2018-2023)
2.2.3 Orally Disintegrating Drug Forecasted Market Size by Region (2024-2029)
2.3 Orally Disintegrating Drug Market Dynamics
2.3.1 Orally Disintegrating Drug Industry Trends
2.3.2 Orally Disintegrating Drug Market Drivers
2.3.3 Orally Disintegrating Drug Market Challenges
2.3.4 Orally Disintegrating Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orally Disintegrating Drug Players by Revenue
3.1.1 Global Top Orally Disintegrating Drug Players by Revenue (2018-2023)
3.1.2 Global Orally Disintegrating Drug Revenue Market Share by Players (2018-2023)
3.2 Global Orally Disintegrating Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orally Disintegrating Drug Revenue
3.4 Global Orally Disintegrating Drug Market Concentration Ratio
3.4.1 Global Orally Disintegrating Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orally Disintegrating Drug Revenue in 2022
3.5 Orally Disintegrating Drug Key Players Head office and Area Served
3.6 Key Players Orally Disintegrating Drug Product Solution and Service
3.7 Date of Enter into Orally Disintegrating Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orally Disintegrating Drug Breakdown Data by Type
4.1 Global Orally Disintegrating Drug Historic Market Size by Type (2018-2023)
4.2 Global Orally Disintegrating Drug Forecasted Market Size by Type (2024-2029)
5 Orally Disintegrating Drug Breakdown Data by Application
5.1 Global Orally Disintegrating Drug Historic Market Size by Application (2018-2023)
5.2 Global Orally Disintegrating Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Orally Disintegrating Drug Market Size (2018-2029)
6.2 North America Orally Disintegrating Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Orally Disintegrating Drug Market Size by Country (2018-2023)
6.4 North America Orally Disintegrating Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Orally Disintegrating Drug Market Size (2018-2029)
7.2 Europe Orally Disintegrating Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Orally Disintegrating Drug Market Size by Country (2018-2023)
7.4 Europe Orally Disintegrating Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orally Disintegrating Drug Market Size (2018-2029)
8.2 Asia-Pacific Orally Disintegrating Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Orally Disintegrating Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Orally Disintegrating Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Orally Disintegrating Drug Market Size (2018-2029)
9.2 Latin America Orally Disintegrating Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Orally Disintegrating Drug Market Size by Country (2018-2023)
9.4 Latin America Orally Disintegrating Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orally Disintegrating Drug Market Size (2018-2029)
10.2 Middle East & Africa Orally Disintegrating Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Orally Disintegrating Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Orally Disintegrating Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Detail
11.1.2 Johnson and Johnson Business Overview
11.1.3 Johnson and Johnson Orally Disintegrating Drug Introduction
11.1.4 Johnson and Johnson Revenue in Orally Disintegrating Drug Business (2018-2023)
11.1.5 Johnson and Johnson Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Orally Disintegrating Drug Introduction
11.2.4 GSK Revenue in Orally Disintegrating Drug Business (2018-2023)
11.2.5 GSK Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Detail
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Orally Disintegrating Drug Introduction
11.3.4 Otsuka Revenue in Orally Disintegrating Drug Business (2018-2023)
11.3.5 Otsuka Recent Development
11.4 Vartris
11.4.1 Vartris Company Detail
11.4.2 Vartris Business Overview
11.4.3 Vartris Orally Disintegrating Drug Introduction
11.4.4 Vartris Revenue in Orally Disintegrating Drug Business (2018-2023)
11.4.5 Vartris Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Orally Disintegrating Drug Introduction
11.5.4 Teva Revenue in Orally Disintegrating Drug Business (2018-2023)
11.5.5 Teva Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Orally Disintegrating Drug Introduction
11.6.4 Pfizer Revenue in Orally Disintegrating Drug Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Orally Disintegrating Drug Introduction
11.7.4 Eli Lilly and Company Revenue in Orally Disintegrating Drug Business (2018-2023)
11.7.5 Eli Lilly and Company Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Orally Disintegrating Drug Introduction
11.8.4 Merck Revenue in Orally Disintegrating Drug Business (2018-2023)
11.8.5 Merck Recent Development
11.9 Eisai
11.9.1 Eisai Company Detail
11.9.2 Eisai Business Overview
11.9.3 Eisai Orally Disintegrating Drug Introduction
11.9.4 Eisai Revenue in Orally Disintegrating Drug Business (2018-2023)
11.9.5 Eisai Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Detail
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Orally Disintegrating Drug Introduction
11.10.4 AstraZeneca Revenue in Orally Disintegrating Drug Business (2018-2023)
11.10.5 AstraZeneca Recent Development
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Detail
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Orally Disintegrating Drug Introduction
11.11.4 Bristol-Myers Squibb Revenue in Orally Disintegrating Drug Business (2018-2023)
11.11.5 Bristol-Myers Squibb Recent Development
11.12 Conquer
11.12.1 Conquer Company Detail
11.12.2 Conquer Business Overview
11.12.3 Conquer Orally Disintegrating Drug Introduction
11.12.4 Conquer Revenue in Orally Disintegrating Drug Business (2018-2023)
11.12.5 Conquer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock